Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Constitution of the Board of Directors in Genmab and Grant of Warrants to Employees15 Apr 2009
Arzerra™ (ofatumumab) Granted Priority Review by FDA3 Apr 2009
Genmab's Total Number of Voting Rights and Total Share Capital31 Mar 2009
Genmab A/S Summons Annual General Meeting25 Mar 2009
Genmab to Attend Kempen & Co Life Sciences Conference 200923 Mar 2009
Genmab's Annual Report 200817 Mar 2009
Articles of Association of Genmab A/S dated March 4, 200910 Mar 2009
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
4 Mar 2009
Genmab to Attend Two March Investor Conferences26 Feb 2009
Arzerra(TM) (ofatumumab) MAA Accepted by EMEA26 Feb 2009
Financial Statements Release 200824 Feb 2009
Genmab Announces Year End 2008 Financial Results24 Feb 2009
  • Previous
  • 1
  • More pages
  • 107
  • 108
  • 109
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863